奥福格列酮与肥胖伴或不伴2型糖尿病成人血压的关联:ATTAIN-1和ATTAIN-2试验的事后分析
本文为ATTAIN-1和ATTAIN-2试验的事后分析,评估奥福格列酮(合并剂量)与安慰剂对肥胖或超重成人(伴或不伴2型糖尿病)血压的影响。第72周时,各基线亚组收缩压降幅一致且无明确异质性,舒张压降幅在多数亚组可见,中介分析提示收缩压降幅大部分由体重下降介导。血压相关不良事件少见且多为轻中度,但奥福格列酮组多于安慰剂组。
要点
- 第72周收缩压降幅在各基线亚组一致,无明确异质性(交互P均>0.10)。
- 中介分析估计ATTAIN-1和ATTAIN-2中收缩压降幅分别有58.3%和80.8%由体重下降介导(P<0.001)。
- 血压相关不良事件少见、多为轻中度,但奥福格列酮组多于安慰剂组。
核心结论
- 在ATTAIN-1和ATTAIN-2的事后分析中,收缩压降幅在各基线亚组 broadly 一致,无明确异质性证据;变化估计大部分由体重下降介导,对血压的潜在非体重依赖效应需进一步评估。
研究设计与样本
- ATTAIN-1和ATTAIN-2试验的事后分析,纳入随机接受奥福格列酮(合并剂量)或安慰剂的成人肥胖或超重患者(ATTAIN-1不伴2型糖尿病,ATTAIN-2伴2型糖尿病)。
- 采用重复测量混合模型评估第72周血压较基线的变化,并用探索性中介分析评估体重变化与收缩压的关联。
主要发现
- 探索性亚组分析显示,ATTAIN-1和ATTAIN-2中各基线亚组收缩压均降低,无明确异质性证据(交互P均>0.10)。
- ATTAIN-1中大多数基线亚组舒张压降低;ATTAIN-2中基线舒张压≥80 mmHg者较基线舒张压<80 mmHg者舒张压降幅更大(交互P=0.002)。
- 第72周时,ATTAIN-1和ATTAIN-2中奥福格列酮组达到研究访视诊室血压正常的比例在数值上高于安慰剂组。
- 中介分析估计,ATTAIN-1和ATTAIN-2中收缩压降幅分别有58.3%和80.8%由奥福格列酮诱导的体重下降介导(P<0.001)。
- 血压相关不良事件少见,但奥福格列酮组较安慰剂组更频繁,且多为轻中度。
局限性
- 原文结论指出,对血压的潜在非体重依赖效应需进一步评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ABSTRACT Introduction This post hoc analysis assessed the association between orforglipron and blood pressure in adults with obesity or overweight without (ATTAIN-1) and with Type 2 diabetes (T2D; ATTAIN-2). Methods This study included ATTAIN-1 and ATTAIN-2 participants randomized to receive orforglipron (pooled doses) or placebo. A mixed model of repeated measures was used to assess changes in blood pressure across baseline subgroups at Week 72. The association between weight change and systolic blood pressure (SBP) was evaluated by exploratory mediation analysis. Blood-pressure-related adverse events were also reported. Results Exploratory subgroup analyses reflected reductions in SBP across all baseline subgroups with no clear evidence of heterogeneity in ATTAIN-1 and ATTAIN-2 (all interaction p > 0.10). Reductions in diastolic blood pressure (DBP) were observed across most of the baseline subgroups in ATTAIN-1, while a greater reduction in DBP was observed among participants with baseline DBP ≥ 80 mmHg compared with those who had baseline DBP < 80 mmHg in ATTAIN-2 (interaction p = 0.002). At Week 72, numerically greater proportions of orforglipron-treated participants achieved study-visit-office normal blood pressure than placebo in ATTAIN-1 and -2. Mediation analysis suggests that 58.3% and 80.8% of the reduction in SBP was estimated to be mediated by orforglipron-induced weight reduction in ATTAIN-1 and -2, respectively (p < 0.001). Low blood pressure-related adverse events were uncommon but more frequent with orforglipron treatment than with placebo, and were mostly mild to moderate in severity. Conclusion In these post hoc analyses of ATTAIN-1 and -2, reductions in SBP were broadly consistent across baseline subgroups, with no clear evidence of heterogeneity. The changes were estimated to be largely mediated by weight loss, and potential weight-independent effects on blood pressure require further evaluation.
引用
- Diabetes, Obesity and Metabolism:Association Between Orforglipron and Blood Pressure in Adults With Obesity With or Without Type 2 Diabetes: Post Hoc Analyses From ATTAIN‐1 and ATTAIN‐2 Trials
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。